AYA - Artrya Limited

[System]

Artrya Limited (AYA) is a medical-technology company focused on commercialising its patented Salix suite of software products to improve detection and treatment of coronary artery disease (CAD). Salix uses artificial intelligence (AI) to automate the analysis and diagnosis of heart computed tomography (CT) scans, and help clinicians identify and manage patients at risk of a heart attack.

Artrya’s Salix Coronary Anatomy (SCA) Software as a Service (SaaS) product provides clinicians with rapid reporting of one of the strongest predictors of heart attack: Vulnerable Plaque. Named for its propensity to rupture and cause heart attack, Vulnerable Plaque is difficult and time-consuming to identify manually. As a result, Vulnerable Plaque, a leading cause of heart attack, is rarely reported.

Current practices to report CAD focus on the calcification and consequent narrowing of coronary arteries. Salix’s breakthrough technology analyses Coronary Computed Tomography Angiography (CCTA) scans to map Vulnerable Plaque and other coronary risk biomarkers. Salix generates a personalised 3D heart model and rapidly delivers an international-standard diagnostic report.

Already under development is Artrya’s next product, Salix Coronary Flow (SCF). Because SCF provides a non-invasive assessment of coronary blood flow, it could potentially reduce the number of unnecessary Invasive Coronary Angiogram (ICA) procedures.

It is anticipated that AYA will list on the ASX on 26 November 2021.

Artrya | AI-Driven Healthcare Tech Company

Artrya partners with clinics receiving chest pain patients to deliver new models of cardiovascular care based on AI.

www.artrya.com

 

[Dona Ferentes]

Listing date	26 November 2021 12:30 PM AEDT##
Contact details	https://www.artrya.com/ Ph: +61 8 6478 7816
Principal Activities	Artrya Limited is a medical technology company developing software which automates the analysis of heart computed tomography (CT) scans to assist in the diagnosis of Coronary Artery Disease.
GICS industry group	TBA
Issue Price	AUD 1.35
Issue Type	Ordinary Fully Paid Shares
Security code	AYA
Capital to be Raised	$40,000,000
Expected offer close date	29 October 2021
Underwriter	Bell Potter Securities Limited (Underwriter/Lead Manager)

 

[Country Lad]

No comment here since listing. It has come up on scans over the past week or 2 so thought I should have a look. Being essentially lazy I will paste some quotes from here ^there.

Artrya’s flagship product, the Salix Coronary Anatomy (SCA), is a breakthrough technology that can detect vulnerable plaque biomarkers from a CCTA (Coronary CT Angiography) within minutes.

A vulnerable plaque is essentially a soft plaque that ruptures and causes clots to block arteries. The plaque is particularly unstable, and prone to produce sudden major problems such as a heart attack or stroke.

In the UK, the company has a four-year contract in place to supply 1,250 National Health Service (NHS) Trust Hospitals with the product and is now ready to launch it here. It is awaiting FDA approval.

I missed the opportunity at $0.47 but see it as a technical buy if it breaks 57.

 

[Country Lad]

One of the biotechs I am holding.. Good news coning with the usual capital raise.

12 February 2025

Artrya secures multi-year commercial contract with Sonic Healthcare Australia

Highlights

• Artrya secures commercial contract with Sonic Healthcare Australia - Radiology for use of Salix® Coronary Anatomy platform for coronary artery disease assessment at the point of care

• The three-year contract will generate revenue through a Software-as-a-Service (SaaS) subscription model, with initial revenue anticipated in Q4 FY25.

• Sonic Healthcare is the second largest diagnostic imaging provider in Australia, with more than 125 radiology centres, and the first large radiology group in Australia to leverage Salix to assist in the diagnosis of coronary artery disease.

 

[Dona Ferentes]

beginning to get interesting

since listing

 

[Country Lad]

beginning to get interesting

I have been interested in their technology for quite a while - didn't buy on the break at 38 and again at 47 but third time lucky as 57 as per previous post and chart

 

[finicky]

I recognise your non-exec chairman as the retired M.D of one of my fave companies, that being Imdex (IMD). He was popular with shareholders. He was buying on market up to Mar 2023.

Not Held